Aptevo said its multispecific platform will be presented at a cancer-immunotherapy meeting in November. The filing gives no study results or business change, so it does not change the company's outlook.
The presentation may draw attention to Aptevo's platform, but the filing reports no study results, new deal, or change in sales. It gives no clear reason to change the view of the company's business.
Follow Aptevo Therapeutics Inc. (APVO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for APVO